Actavis’ Investment Venture To Acquire Stake In Techpool Bio-Pharma
This article was originally published in PharmAsia News
Investor firm Smart Nice, majority-owned by pharmaceutical company Actavis, will accept 20 million shares of Techpool Bio-Pharma from Guangzhou Bopu and buy another 20 million shares at 5 yuan per share. Shanghai Industrial Pharmaceutical Investment and its subsidiary Huarui Investments will decrease their equity in Techpool from 51 percent to 40.8 percent, while Smart Nice will become a strategic investor with 40 percent stake. According to sources, both companies have signed an MOU to collaborate in the areas of medical science, technology, business operation and pharmaceutical-related fields. (Click here for more - Chinese language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.